Skip to main content

Advertisement

SpringerLink
Log in

Effects of Pien Tze Huang (片仔癀) on angiogenesis in vivo and in vitro

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the anti-angiogenic effects of Pien Tze Huang (片仔癀, PZH) in vivo and in vitro.

Methods

Human umbilical vein endothelial cells (HUVECs) were treated with 0 mg/mL, 0.25 mg/mL, 0.5 mg/mL, and 1 mg/mL of PZH for 24 h, 48 h and 72 h, respectively. Chicken embryo chorioallantoic membrane (CAM) model was used to evaluate in vivo angiogenesis. An ECMatrix gel system was used to evaluate in vitro angiogenesis by examining the tube formation of HUVECs. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed to determine HUVEC viability. Cell density of HUVECs was observed by phasecontrast microscopy. HUVEC migration was determined by wound healing method. The mRNA and protein expression of vascular endothelial growth factor A (VEGF-A) and basic fibroblast growth factor (bFGF) in both HUVEC and human colon adenocarcinoma cells (HT-29) was examined by reverse transcription polymerase chain reaction (RT-PCR) and enzyme linked immune sorbent assay (ELISA), respectively.

Results

PZH treatment significantly reduced the total number of blood vessels compared with the untreated control in the chicken embryos and resulted in a significant decrease in capillary tube formation and cell density of HUVECs (P<0.05). In addition, treatment with 0.25–1 mg/mL of PZH for 24 h, 48 h, and 72 h respectively reduced cell viability by 9%–52%, 24%–87% or 25%–87%, compared with the untreated control cells (P<0.05). Moreover, PZH treatment decreased the migration of HUVECs. Furthermore, PZH dose-dependently suppressed the expression of VEGF-A and bFGF on both mRNA and protein levels (P<0.05).

Conclusion

PZH could inhibit angiogenesis in vivo in CAM model and in vitro on HUVECs, suggesting that inhibiting tumor angiogenesis might be one of the mechanisms by which PZH treats cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial award lecture. Cancer Res 1986;46:467–473.

    PubMed  CAS  Google Scholar 

  3. Folkman J, Shing Y. Angiogenesis. J Biol Chem1992;267:10931–10934.

    PubMed  CAS  Google Scholar 

  4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27–31.

    Article  PubMed  CAS  Google Scholar 

  5. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1–18.

    Article  PubMed  CAS  Google Scholar 

  6. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039–3051.

    PubMed  CAS  Google Scholar 

  7. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222–243.

    Article  PubMed  Google Scholar 

  8. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.

    Article  PubMed  CAS  Google Scholar 

  9. Breier G, Risau W. The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 1996;6:454–456.

    Article  PubMed  CAS  Google Scholar 

  10. Stromblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996;3:881–885.

    Article  PubMed  CAS  Google Scholar 

  11. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671–674.

    Article  PubMed  CAS  Google Scholar 

  12. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29:3–9.

    PubMed  CAS  Google Scholar 

  13. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10–14.

    PubMed  CAS  Google Scholar 

  14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.

    Article  PubMed  CAS  Google Scholar 

  15. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222–3230.

    Article  PubMed  CAS  Google Scholar 

  16. Vlodavsky CR, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of “PDGFBB and FGF-2”. Nat Med 2003;9:604–613.

    Article  Google Scholar 

  17. Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159–178.

    Article  PubMed  CAS  Google Scholar 

  18. Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009;19:310–317.

    Article  PubMed  CAS  Google Scholar 

  19. Muñoz-Chápuli R, Quesada AR, Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2 2004;61:2224–2243.

    Google Scholar 

  20. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27:4865–4873.

    Article  PubMed  CAS  Google Scholar 

  21. Higa GM, Abraham J. Biological mechanisms of bevacizumabassociated adverse events. Expert Rev Anticancer Ther 2009;9:999–1007.

    Article  PubMed  CAS  Google Scholar 

  22. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465–477.

    Article  PubMed  CAS  Google Scholar 

  23. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007;9:767–776.

    Article  PubMed  CAS  Google Scholar 

  24. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. EMBO Reports 2009;10:194–200.

    Article  PubMed  CAS  Google Scholar 

  25. Zhao J, Jiang P, Zhang WD. Molecular networks for the study of TCM pharmacology. Brief Bioinform 2009;11:417–430.

    Article  PubMed  Google Scholar 

  26. Lin JM, Chen YQ, Wei LH, Chen XZ, Xu W, Hong ZF, et al. Hedyotis Diffusa Willd extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells. Int J Oncol 2010;37:1331–1338.

    Article  PubMed  Google Scholar 

  27. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Beijing: Chinese Medical Science and Technology Press; 2010:573–575.

    Google Scholar 

  28. Xu YY, Yu EX. Clinical analysis of the effect of Pien Tze Huang in treatment of 42 patients with moderate or advanced liver cancer. Shanghai J Tradit Chin Med (Chin) 1994;12:4–5.

    Google Scholar 

  29. Gu ZX. Therapeutical observation of advanced colon cancer. Chin Tradit Patent Med (Chin) 1993;15:23.

    Google Scholar 

  30. Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF, Sferra TJ, et al. Pien Tze Huang-induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3. Chin J Integr Med 2011;17:685–690.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China

    A.-ling Shen  (沈阿灵), Li-ya Liu  (刘丽雅), Jiu-mao Lin  (林久茂), Qun-chuan Zhuang  (庄群川), Zhen-feng Hong  (洪振丰) & Jun Peng  (彭 军)

  2. Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China

    A.-ling Shen  (沈阿灵), Li-ya Liu  (刘丽雅), Jiu-mao Lin  (林久茂) & Qun-chuan Zhuang  (庄群川)

  3. Postdoctor Workstation, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., Fujian, 363000, China

    Fei Hong  (洪 绯) & Jun Peng  (彭 军)

Authors
  1. A.-ling Shen  (沈阿灵)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fei Hong  (洪 绯)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-ya Liu  (刘丽雅)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiu-mao Lin  (林久茂)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qun-chuan Zhuang  (庄群川)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhen-feng Hong  (洪振丰)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Peng  (彭 军)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Peng  (彭 军).

Additional information

Surpported by the National Natural Science Foundation of China (No. 81073097), the Developmental Fund of Chen Ke-ji Integrative Medicine (No. CKJ 2011001), and the Natural Science Foundation of Fujian Province of China (No. 2010J01195)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shen, Al., Hong, F., Liu, Ly. et al. Effects of Pien Tze Huang (片仔癀) on angiogenesis in vivo and in vitro . Chin. J. Integr. Med. 18, 431–436 (2012). https://doi.org/10.1007/s11655-012-1121-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-012-1121-z

Keywords

Search

Navigation